BACKGROUND AND PURPOSE: EnF is a newly described measure of proportional tumor enhancement derived from DCE-MR imaging. The aim of this study was to assess the relationship between EnF and the more established DCE-MR imaging parameters: K trans , v e , and v p .
D
CE-MR imaging allows characterization of the vascular microenvironment in tumors by measurement of a range of parameters that reflect specific physiologic characteristics. One of the simplest measures is the IAUC during a given time, usually 60 seconds (IAUC 60 ). 1 While IAUC is simple to calculate and has been shown to be a reliable and reproducible parameter, 2 it has no physiologic specificity. More complex postprocessing analysis uses pharmacokinetic modeling to measure K trans (reflecting both flow and permeability), v e , v p , and rCBV. 3 These complex measures have greater physiologic specificity and relate predictably to various aspects of tumor biology. In gliomas, measures of blood volume, both rCBV and v p , have demonstrated excellent discrimination of tumor grade, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] subtype, 15 and genotype 16, 17 ; and K trans also discriminates grade. 13, [18] [19] [20] Both blood volume and K trans have been identified as prognostic indicators of survival in glioma, [21] [22] [23] [24] [25] but unlike blood volume, the relationship between K trans and patient survival is independent of its relationship with histologic grade. 23 Recent investigators studying solid masses of the abdomen have proposed a simple measure of bulk tumor perfusion from DCE-MR imaging, the EnF or perfused proportion, 26, 27 which is the ratio of enhancing to total tumor volume. A CT variant of this measure has shown promise in differentiating stable from progressive disease and in predicting time to progression following first-line chemotherapy in ovarian cancer. 28 Measurements of IAUC can be used to reproducibly stratify voxels as enhancing or nonenhancing for a definition of the EnF. Because the IAUC is a continuous variable, the distinction between enhancing and nonenhancing can be defined by the presence of enhancement (IAUC Ͼ 0 mmol.s) or by use of a threshold value to define a minimal acceptable level of enhancement. In a previous study, we have demonstrated that EnF defined at a threshold of IAUC 60 Ͼ 2.5 mmol.s pro-vides optimal discrimination between low-and high-grade gliomas. 29 The value of EnF in an individual tumor will be affected by a number of variations in the tumor vascular microenvironment. Areas of necrosis or nonperfusion will clearly fail to enhance, but enhancement may also not occur in viable tumor if perfusion pressure and perfusion rates are low relative to the vascular half-life of the contrast media. The specific aim of this study was to investigate the effects of variations in DCE-MR imaging parameters, K trans , v e , and v p , on measured EnF in glioma.
Materials and Methods

Patients
The local research ethics committee approved the study, and all patients gave informed consent before recruitment. Patients were identified via the neuro-oncology multidisciplinary team meetings at Salford Royal National Health Service Foundation Trust. All imaging was performed before surgery. All tumors were histologically confirmed as gliomas and graded according to the WHO classification criteria. 30 All patients with grade IV tumors received corticosteroid treatment for a minimum of 48 hours before imaging. None received any other form of treatment at the time of imaging or before surgery. Findings in this group of patients describing the differences in EnF between low-and high-grade tumors have been reported previously.
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Data Acquisition
Imaging was performed at the University of Manchester Magnetic Resonance Imaging Facility (Hope Hospital, Salford, United Kingdom) by using a sensitivity encoding head coil on a 3T Achieva system (Philips Medical Systems, Best, the Netherlands). DCE-MR imaging was acquired in a sagittal oblique orientation to incorporate the internal carotid artery for measurement of an AIF. Four precontrast T1 fast-field echo (radio-frequency-spoiled gradient-echo) sequences (␣ ϭ 2°, 5°, 10°, and 16°) were acquired in the same geometry for calculation of baseline T1 maps (TR, 3.5 ms; TE, 
Data Analysis
An experienced radiologist (S.J.M.) manually defined VOIs for each tumor on the postcontrast T1 geometrically matched sequences, drawing around signal intensity abnormality/contrast enhancement by using a technique that has previously shown good interobserver agreement (intraclass correlation coefficient, Ͼ0.94), 31 before histologic diagnosis was confirmed. Postprocessing analysis was performed by using in-house software (Manchester Dynamic Modeling) and the extended Tofts and Kermode pharmacokinetic model. 3 Automated AIFs were generated from an appropriately chosen section that included the internal carotid artery. 32 Parametric maps of K trans , v p , v e , and IAUC 60 were produced. For each tumor, EnF IAUC60Ͼ0 was calculated by dividing the enhancing volume (volume of voxels with an IAUC 60 Ͼ0 mmol.s) by the total volume of the VOI. EnF IAUC60Ͼ2.5 was calculated by using a previously identified optimal threshold of IAUC 60 (Ͼ2.5 mmol.s), above which voxels were considered to be enhancing. This optimized threshold was defined on an initial dataset of 5 grade II and 10 grade IV gliomas to identify the optimum IAUC 60 threshold for distinguishing histologic grade.
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Statistical Analysis
All statistical analyses were performed by using SPSS, Version 15.0 (SPSS, Chicago, Illinois). Data were not normally distributed; therefore, nonparametric analyses were performed. Tumors were grouped according to grade (II, III, and IV), and grade II tumors were further separated according to histologic subtype (astrocytomas and tumors with an oligodendroglial component). For each tumor grade and histologic subtype of the grade II tumors, scatterplots of median values of the DCE-MR imaging parameters versus EnF IAUC60Ͼ0 and EnF IAUC60Ͼ2.5 were generated. Comparison between individual DCE-MR imaging parameters and both EnF IAUC60Ͼ0 and EnF IAUC60Ͼ2.5 was performed by using a bivariate Spearman rank correlation analysis for grade II and IV tumors and the 2 histologic subgroups of grade II tumors; there were insufficient numbers in the grade III group to perform this analysis. On finding significant correlations, all parameters were entered into a multiple linear regression analysis by using a forward entry model, with an entry criterion of P Ͻ .05 to evaluate any cross-correlation between parameters.
Results
We recruited 42 patients: 18 women and 24 men, with a mean age of 49 Ϯ 16 years (range, 19 -77 years). There were a total of 43 tumors, because 1 patient had bilateral grade II tumors, each of distinct histologic subtype (astrocytoma and oligodendroglioma). The 16 grade II tumors included 6 astrocytomas (4 diagnosed by biopsy and 2 by surgical debulking), 3 oligoastrocytomas (all surgically debulked), and 7 oligodendroglio- mas (1 biopsied and 6 surgically debulked). The 3 grade III tumors were all diagnosed by surgical debulking and included 2 anaplastic astrocytomas and 1 anaplastic oligodendroglioma. The 24 grade IV gliomas included 23 glioblastoma multiformes (9 biopsied and 14 surgically debulked) and 1 gliosarcoma (surgically debulked). All 10 of the oligodendrogliomas/ oligoastrocytomas in this study exhibited loss of heterozygosity of 1p/19q. In the group of grade II tumors, EnF IAUC60Ͼ0 correlated with v p (P Ͻ .0005; Spearman rho correlation coefficient ϭ 0.838; R 2 ϭ 0.6245; Table 1 and Fig 1A) , but not with K trans (P ϭ .926) or v e (P ϭ .213). Similarly, there was a significant correlation between EnF IAUC60Ͼ2.5 and v p (P ϭ .003; Spearman rho correlation coefficient ϭ 0.697; R 2 ϭ 0.4727; Table 1 and Fig 1B) , but not with K trans (P ϭ .996) or v e (P ϭ .721). In the subgroup of grade II astrocytomas, neither EnF IAUC60Ͼ0 or EnF IAUC60Ͼ2.5 correlated with v p (P ϭ .266 and P ϭ .208), K trans (P ϭ .329 and P ϭ .329), or v e (P ϭ .486 and P ϭ .329). In the subgroup of grade II tumors with an oligodendroglial component, v p correlated with both EnF IAUC60Ͼ0 and EnF IAUC60Ͼ2.5 (P ϭ .013; Spearman rho correlation coefficient ϭ 0.745; R 2 ϭ 0.604 and P ϭ .048; Spearman rho correlation coefficient ϭ 0.636; R 2 ϭ 0.397), but not with K trans (P ϭ .440 and P ϭ .483) or v e (P ϭ .777 and P ϭ .603).
In grade IV tumors, EnF IAUC60Ͼ0 correlated with both K trans (P ϭ .001; Spearman rho correlation coefficient ϭ 0.633; R 2 ϭ 0.3501; Table 2 and Fig 2A) and v p (P ϭ .01; Spearman rho correlation coefficent ϭ 0.514; R 2 ϭ 0.1564; Table 2 and Fig 3A) , but not with v e (P ϭ .654). Again, similar relationships were seen between EnF IAUC60Ͼ2.5 and K trans (P Ͻ .0005; Spearman rho correlation coefficient ϭ 0.770; R 2 ϭ 0.4699; Table 2 and Fig 2B) , v p (P ϭ .007; Spearman rho correlation coefficient ϭ 0.537; R 2 ϭ 0.2429; Table 2 and Fig 3B) , and v e (P ϭ .154). Multiple linear regression analysis demonstrated K trans as the only significant independent correlate of both EnF IAUC60Ͼ0 (P ϭ .002 and R 2 ϭ 0.592) and EnF IAUC60Ͼ2.5 (P ϭ .0002 and R 2 ϭ 0.686). Crosscorrelation was found between K trans and v p (P ϭ .014; Spearman rho correlation coefficient ϭ 0.496; R 2 ϭ 0.4618; Table 2 and Fig  4) . The addition of v p did not significantly influence the multiple linear regression model.
Discussion
This study examined the relationship between EnF and characteristics of the tumoral vascular microenvironment defined by the model-based parameters K trans , v p , and v e . EnF is based on the IAUC and has advantages in that it is relatively simple to perform, is unlikely to be influenced significantly by variations in scanner and sequence type, and does not rely on complex postprocessing pharmacokinetic modeling techniques. 1, 3, 33 Thus, it is more suitable for use within the clinical setting and for multicenter studies because it is less reliant on the technical expertise required for more complex analysis processes.
Although EnF uses IAUC to classify pixels as enhancing or nonenhancing, it is a distinct metric with important differences from the widely used vascular biomarkers derived from DCE-MR imaging and DCE-CT. EnF will be affected by a wider range of physiologic processes. These include those that influence local IAUC in enhancing tissue and physiologic conditions that prevent perfusion or enhancement. The volume of necrotic and of viable but inadequately perfused tissue directly contributes to the measurement. EnF will, therefore, be influenced by regional arterial-venous pressure differences and tumor interstitial pressure. In a study of ovarian and colorectal cancer treated with CDP860, a selective platelet-derived growth factor inhibitor known to cause primary decreases in tumor interstitial pressure, increases in EnF occurred rapidly after administration of the drug, 26 though model-based parameters, including IAUC, K trans , v e , and v p showed no change. Cerebral tumors develop in a unique physiologic environment in which increases in tumor volume directly affect the pressure of the compartment in which they develop. Conse- quently, changes in interstitial pressure, which is equivalent to intracranial pressure, directly reflect the volume and growth rate of the tumor and its components. Hence, a rapidly growing glioma may be expected to develop an interstitial pressure that exceeds perfusion pressures in the tumor core, which will consequently fail to enhance. This process will result in significant hypoperfusion and hypoxia in the central parts of the tumor. These effects will, in turn, result in release of angiogenic cytokines, particularly VEGF. Glioblastomas produce higher levels of VEGF than any other tumor, which has led to recent trials of antiangiogenic therapy, which have been associated with increased survival. 34, 35 Thus, EnF may provide novel information regarding both tumor development and therapeutic response to novel agents.
In this study, we have attempted to increase our understanding of the behavior of EnF as a putative biomarker for glioma by examining the relationship between EnF and conventional biomarkers of enhancing tumor tissue. This work confirms that EnF, both thresholded and unthresholded, may be of value as a biomarker in glioma. At presentation, it could provide a simple, robust, and model-free alternative to parameters derived from pharmacokinetic analysis of DCE-MR imaging data. The manner in which EnF relates to the DCE-MR imaging parameters depends on the features of the vascular microenvironment. In low-grade tumors, vessel permeability is low and the blood-brain barrier is essentially intact; therefore, contrast remains mostly within the vascular space and EnF correlates with v p (Fig 1) . Conversely, in high-grade tumors, there is high blood flow and local disruption of the blood-brain barrier with marked leakage of contrast into the extravascular extracellular space. In this group of tumors, both K trans , which reflects flow and capillary permeability, and v p correlate with EnF (Figs 2 and 3) . However, multiple regression analysis shows that v p is a covariate of K trans (Fig 4) . No correlation between EnF and v e was found for either grade II or grade IV tumors.
In high-grade tumors, K trans has been shown to predict prognosis independent of cerebral blood volume measurements. 23 At the time of analysis, survival data were not available for this group of patients; therefore, the relationship between EnF and patient outcome cannot be reported. However, if this prognostic relationship does hold for EnF, then the technique may provide a potentially important prognostic marker.
The main limitations with this study were the small num- 
Conclusions
EnF is a simple, model-free, and robust metric that does not require the complex pharmacokinetic modeling necessary for calculation of v p and K trans . It is a distinct entity and influenced by a wide range of physiologic processes. However, EnF correlates with v p in grade II glioma and K trans in grade IV glioma; and given the relationships of K trans and v p to prognosis, tumor subtype, and genotype in glioma, measures of EnF have the potential to be an important adjunctive biomarker.
